Lenalidomide plus rituximab induced durable responses in NHL Healio The combination of lenalidomide and rituximab produced durable responses in a cohort of patients with relapsed/refractory or indolent non-Hodgkin's lymphoma, according to results of a phase 2 study. Thirty patients received weekly rituximab (Rituxan, ... |
